455 related articles for article (PubMed ID: 34486798)
21. Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection.
Akbarzadeh-Khiavi M; Torabi M; Rahbarnia L; Safary A
Infection; 2022 Apr; 50(2):295-308. PubMed ID: 34902115
[TBL] [Abstract][Full Text] [Related]
22. TRPV2-spike protein interaction mediates the entry of SARS-CoV-2 into macrophages in febrile conditions.
Xu J; Yang Y; Hou Z; Jia H; Wang Y
Theranostics; 2021; 11(15):7379-7390. PubMed ID: 34158856
[TBL] [Abstract][Full Text] [Related]
23. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
24. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
[TBL] [Abstract][Full Text] [Related]
25. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
Hoang TN; Pino M; Boddapati AK; Viox EG; Starke CE; Upadhyay AA; Gumber S; Nekorchuk M; Busman-Sahay K; Strongin Z; Harper JL; Tharp GK; Pellegrini KL; Kirejczyk S; Zandi K; Tao S; Horton TR; Beagle EN; Mahar EA; Lee MYH; Cohen J; Jean SM; Wood JS; Connor-Stroud F; Stammen RL; Delmas OM; Wang S; Cooney KA; Sayegh MN; Wang L; Filev PD; Weiskopf D; Silvestri G; Waggoner J; Piantadosi A; Kasturi SP; Al-Shakhshir H; Ribeiro SP; Sekaly RP; Levit RD; Estes JD; Vanderford TH; Schinazi RF; Bosinger SE; Paiardini M
Cell; 2021 Jan; 184(2):460-475.e21. PubMed ID: 33278358
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 Spike protein enhances ACE2 expression via facilitating Interferon effects in bronchial epithelium.
Zhou Y; Wang M; Li Y; Wang P; Zhao P; Yang Z; Wang S; Zhang L; Li Z; Jia K; Zhong C; Li N; Yu Y; Hou J
Immunol Lett; 2021 Sep; 237():33-41. PubMed ID: 34228987
[TBL] [Abstract][Full Text] [Related]
27. The S1 Subunit of the SARS-CoV-2 Spike Protein Activates Human Monocytes to Produce Cytokines Linked to COVID-19: Relevance to Galectin-3.
Schroeder JT; Bieneman AP
Front Immunol; 2022; 13():831763. PubMed ID: 35392091
[TBL] [Abstract][Full Text] [Related]
28. Boosted Pro-Inflammatory Activity in Human PBMCs by Lipopolysaccharide and SARS-CoV-2 Spike Protein Is Regulated by α-1 Antitrypsin.
Tumpara S; Gründing AR; Sivaraman K; Wrenger S; Olejnicka B; Welte T; Wurm MJ; Pino P; Kiseljak D; Wurm FM; Janciauskiene S
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360706
[TBL] [Abstract][Full Text] [Related]
29. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
30. JAK inhibitors and COVID-19.
Levy G; Guglielmelli P; Langmuir P; Constantinescu SN
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35459733
[TBL] [Abstract][Full Text] [Related]
31. Ponatinib Protects Mice From Lethal Influenza Infection by Suppressing Cytokine Storm.
Chen S; Liu G; Chen J; Hu A; Zhang L; Sun W; Tang W; Liu C; Zhang H; Ke C; Wu J; Chen X
Front Immunol; 2019; 10():1393. PubMed ID: 31293574
[TBL] [Abstract][Full Text] [Related]
32. Baricitinib attenuates the proinflammatory phase of COVID-19 driven by lung-infiltrating monocytes.
Dobosh B; Zandi K; Giraldo DM; Goh SL; Musall K; Aldeco M; LeCher J; Giacalone VD; Yang J; Eddins DJ; Bhasin M; Ghosn E; Sukhatme V; Schinazi RF; Tirouvanziam R
Cell Rep; 2022 Jun; 39(11):110945. PubMed ID: 35688145
[TBL] [Abstract][Full Text] [Related]
33. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
[TBL] [Abstract][Full Text] [Related]
34. Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice.
Collotta D; Hull W; Mastrocola R; Chiazza F; Cento AS; Murphy C; Verta R; Alves GF; Gaudioso G; Fava F; Yaqoob M; Aragno M; Tuohy K; Thiemermann C; Collino M
Mol Metab; 2020 Sep; 39():101009. PubMed ID: 32413585
[TBL] [Abstract][Full Text] [Related]
35. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
Verma AK; Aggarwal R
Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
[TBL] [Abstract][Full Text] [Related]
36. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
Rodriguez-Garcia JL; Sanchez-Nievas G; Arevalo-Serrano J; Garcia-Gomez C; Jimenez-Vizuete JM; Martinez-Alfaro E
Rheumatology (Oxford); 2021 Jan; 60(1):399-407. PubMed ID: 33020836
[TBL] [Abstract][Full Text] [Related]
37. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840
[TBL] [Abstract][Full Text] [Related]
38. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
39. Natural and Recombinant SARS-CoV-2 Isolates Rapidly Evolve
Shiliaev N; Lukash T; Palchevska O; Crossman DK; Green TJ; Crowley MR; Frolova EI; Frolov I
J Virol; 2021 Oct; 95(21):e0135721. PubMed ID: 34406867
[TBL] [Abstract][Full Text] [Related]
40. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation.
Persaud SP; Ritchey JK; Kim S; Lim S; Ruminski PG; Cooper ML; Rettig MP; Choi J; DiPersio JF
J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34730109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
